CYTK · NASDAQ · Biotechnology

Cytokinetics (CYTK)

Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.

$67.25
After hours−0.36 (−0.53%)
At close$67.61(+0.07%)
  1. Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

    Zacks Investment ResearchClinical